Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients
Thématique(s) / pathologie(s)
- Maladie de Parkinson
Objectifs
Plus d'informations disponibles sur : https://clinicaltrials.gov/ct2/show/record/NCT03162874?term=ambled&cond=Parkinson&draw=2&rank=1
Promoteur
Prexton Therapeutics
Publication(s) scientifique(s)
-
Rascol O et al. A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease. Mov Disord. 2022 May;37(5):1088-1093.
Statut
Résultats publiés
